¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Leukemia Inhibitory Factor Receptor alpha Subunit"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
¿µ¹® receptor ÇÑ±Û ¼ö¿ëü
¼³¸í   
  ¼¼Æ÷Áú³» ¶Ç´Â ¼¼Æ÷Ç¥¸é¿¡ Á¸ÀçÇϴ ºÐÀÚ±¸Á¶·Î¼­ Æ¯À̹°Áú°ú ¼±ÅÃÀûÀ¸·Î °áÇÕÇϸ砰áÇÕ¿¡ ÀÇÇØ Æ¯ÀÌÇÑ »ý¸®Àû ÀÛ¿ëÀ» ³ªÅ¸³½´Ù. ÆéƼµåÈ£¸£¸ó, ½Å°æÀü´Þ¹°Áú, Ç׿ø, º¸Ã¼, ¸é¿ª±Û·ÎºÒ¸°¿¡ ´ëÇÑ ¼¼Æ÷Ç¥¸é ¼ö¿ëü¿Í ½ºÅ×·ÎÀ̵忡 ´ëÇÑ ¼¼Æ÷Áú³» ¼ö¿ëü°¡ ÀÖ´Ù.
¿µ¹® chronic lymphocytic leukemia ÇÑ±Û ¸¸¼º¸²ÇÁ¼º ¹éÇ÷º´
¼³¸í   
  ¹éÇ÷º´(leukemia)¶õ ºñÁ¤»óÀûÀΠ¹éÇ÷±¸ ¼¼Æ÷ÀÇ Áõ½Ä¿¡ ÀÇÇØ ÀϾ´Â º´ÀûÀΠ»óŸ¦ ¸»Çϴµ¥, ÈçÈ÷ ¸»ÃÊÇ÷¾×¿¡ ¹ÌºÐÈ­¼¼Æ÷°¡ ³ªÅ¸³ª¸ç, Á¤»óÀûÀΠÀûÇ÷±¸¼¼Æ÷¿Í ¹éÇ÷±¸¼¼Æ÷, Ç÷¼ÒÆÇÀÇ ±Þ°ÝÇÑ °¨¼Ò¸¦ °¡Á®¿Í Á¤»óÀûÀΠ¼¼Æ÷¿¡ ÀÇÇØ ÇàÇØÁö´Â ¿©·¯ ±â´ÉÀÇ °¨¼Ò¸¦ ÁÖÁõ»óÀ¸·Î ÇÏ¿© º´¿ø¿¡ Ã£¾Æ¿À°Ô µÈ´Ù. µû¶ó¼­ ÀûÇ÷±¸¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ºóÇ÷, ¹éÇ÷±¸¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ¸¹Àº °¨¿°Áõ¼¼(ÈçÈ÷ °É¸®Áö ¾Ê´Â ¼¼±Õ¿¡ ÀÇÇÑ °¨¿°, Áö³ªÄ¡°Ô ÀæÀº °¨±â, Æó·Å µî), Ç÷¼ÒÆÇ¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ÃâÇ÷Áõ»óÀÌ ³ªÅ¸³­´Ù. ¶ÇÇÑ ÇǸ¦ »ý»êÇϴ °ñ¼ö Á¶Á÷¿¡¼­´Â ÀÌ·± ºñÁ¤»óÀûÀΠ¼¼Æ÷ÀÇ Áõ½Ä¸¸À» º¼ ¼ö ÀÖÀ¸¸ç, Á¤»óÀûÀΠ¼¼Æ÷ÀÇ Áõ½ÄÀº º¸±â Èûµé´Ù.
  
  ¸¸¼º¸²ÇÁ¼º ¹éÇ÷º´Àº ¼­¾ç¿¡¼­´Â ºñ±³Àû ¹éÇ÷º´ Áß¿¡¼­ ÈçÇÑ ÇüÀÌÁö¸¸ µ¿¾ç±Ç¿¡¼­´Â ¾ÆÁÖ µå¹® ¹éÇ÷º´ÀÇ ÇüÅÂÀÌ´Ù. ´ë°³ 60¼¼ ÀÌ»óÀÇ °í·ÉÃþ¿¡¼­ ¸¹ÀÌ »ý±â°í 30¼¼ ÀÌÇÏ¿¡¼­´Â °ÅÀǠã¾Æº¼ ¼ö°¡ ¾ø´Ù. Ç÷¾×°Ë»ç»ó¿¡¼­ ¸²ÇÁ±¸ÀÇ ¸¹Àº Áõ°¡¸¦ º¼ ¼ö°¡ ÀÖ°í, ´ë½Å¿¡ ´Ù¸¥ Ç÷¾×¼¼Æ÷µéÀº °¨¼Ò¸¦ ³ªÅ¸³½´Ù. ¹éÇ÷º´ Áß ¿¹Èİ¡ ÁÁÀº ÆíÀ̸破밳 Ä¡·á´Â Ç×¾ÏÁ¦¸¦ ÀÌ¿ëÇÑ È­Çпä¹ýÀ» ¸¹ÀÌ »ç¿ëÇϸç, Æò±Õ »ýÁ¸±â°£Àº 4~5³âÀÌ´Ù.
¿µ¹® leukemia ÇÑ±Û ¹éÇ÷º´
¼³¸í   
  ºñÁ¤»óÀûÀΠ¹éÇ÷±¸ ¼¼Æ÷ÀÇ Áõ½Ä¿¡ ÀÇÇØ ÀϾ´Â º´ÀûÀΠ»óŸ¦ ¸»Çϴµ¥, ÈçÈ÷ ¸»ÃÊ Ç÷¾×¿¡ ¹ÌºÐÈ­¼¼Æ÷°¡ ³ªÅ¸³ª¸ç, Á¤»óÀûÀΠÀûÇ÷±¸¼¼Æ÷¿Í ¹éÇ÷±¸¼¼Æ÷, Ç÷¼ÒÆÇÀÇ ±Þ°ÝÇÑ °¨¼Ò¸¦ °¡Á®¿Í Á¤»óÀûÀΠ¼¼Æ÷¿¡ ÀÇÇØ ÇàÇØÁö´Â ¿©·¯ ±â´ÉÀÇ °¨¼Ò¸¦ ÁÖÁõ»óÀ¸·Î ÇÏ¿© º´¿ø¿¡ Ã£¾Æ¿À°Ô µÈ´Ù. µû¶ó¼­ ÀûÇ÷±¸ ¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ºóÇ÷, ¹éÇ÷±¸¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ¸¹Àº °¨¿°Áõ¼¼(ÈçÈ÷ °É¸®Áö ¾Ê´Â ¼¼±Õ¿¡ ÀÇÇÑ °¨¿°, Áö³ªÄ£ ÀæÀº °¨±â, Æó·Å µî), Ç÷¼ÒÆÇ¼¼Æ÷ÀÇ °¨¼Ò·Î ÀÎÇÑ ÃâÇ÷Áõ»óÀÌ ³ªÅ¸³­´Ù. ¶ÇÇÑ ÇǸ¦ »ý»êÇϴ °ñ¼ö Á¶Á÷¿¡¼­´Â ÀÌ·± ºñÁ¤»óÀûÀΠ¼¼Æ÷ÀÇ Áõ½Ä¸¸À» º¼ ¼ö ÀÖÀ¸¸ç, Á¤»óÀûÀΠ¼¼Æ÷ÀÇ Áõ½ÄÀº º¸±â Èûµé´Ù.
  
  ÀÌ·± ¹éÇ÷º´¿¡´Â ¿©·¯ °¡Áö°¡ Àִ µ¥ Å©°Ô 4°¡Áö·Î ³ª´©¾î ºÐ·ùÇÑ´Ù. Á¤»óÀûÀ¸·Î ¹éÇ÷±¸¼¼Æ÷´Â ¸²ÇÁ°è¼¼Æ÷¿Í °ñ¼ö°è¼¼Æ÷·Î 2ºÐµÇ´Âµ¥, ¹éÇ÷º´ ¶ÇÇÑ ÀÌ·± ¸²ÇÁ°è¼¼Æ÷ÀÇ Áõ½Ä°ú °ñ¼ö°è¼¼Æ÷ÀÇ Áõ½Ä¿¡ µû¶ó ³ª´©¸ç, ±× Áõ»óÀÌ ¾ó¸¶³ª »¡¸® ³ªÅ¸³ª´Â °¡¿¡ µû¶ó ¸¸¼º, ±Þ¼ºÀ¸·Î ³ª´«´Ù. µû¶ó¼­ ¿©±â¿¡´Â ´ÙÀ½ 4°¡ÁöÀÇ ºÐ·ù°¡ ³ª¿À°Ô µÈ´Ù.
  
  -±Þ¼º¸²ÇÁ¼º ¹éÇ÷º´: acute lymphocytic
  
  -±Þ¼º°ñ¼ö¼º ¹éÇ÷º´: acute myelogenous
  
  -¸¸¼º¸²ÇÁ¼º ¹éÇ÷º´: chronic lymphocytic
  
  -¸¸¼º°ñ¼ö¼º ¹éÇ÷º´: chronic myelogenous.
¿µ¹® alpha particles ÇÑ±Û ¾ËÆÄÀÔÀÚ
¼³¸í   
  ¿øÀÚ¿¡ Á¤»óº¸´Ù °ú´Ù, °ú¼ÒÇÑ Áß¼ºÀÚ³ª ¾çÀÚ¸¦ °¡Áö°í Àִ °æ¿ì¿¡ ¿øÀÚ°¡ ¾ÈÁ¤µÇ±â À§Çؼ­ ºØ±«°¡ »ý±ä´Ù. ÀÌ·± ºØ±«¿¡´Â ´ÙÀ½°ú °°Àº 3°¡Áö ¹æ¹ýÀÌ ÀÖ´Ù. ¾ËÆÄ£­ºØ±«´Â ¾ËÆÄÀÔÀÚ¸¦ ¹æÃâÇÏ¿© ¾ÈÁ¤µÇ´Â ¹ý, Áï ¿øÀÚ¹øÈ£´Â 2¾¿ °¨¼ÒÇϰí Áú·®¼ö´Â 4¾¿ °¨¼ÒÇÑ´Ù. ¾ËÆÄÀÔÀÚ¶õ ¾ËÆÄºØ±«¿¡ ÀÇÇØ¼­ »ý±â´Â Çï·ýÀÇ ÇÙ°ú °°Àº ÀÔÀÚ¸¦ ¸»ÇÑ´Ù.
  
  
¿µ¹® alpha-fetoprotein ÇÑ±Û ¾ËÆÄžƴܹé
¼³¸í   
  Å¾ÆÀÇ °£Á¶Á÷À̳ª ¼ÒÈ­±â°ü¿¡¼­ ¸¸µé¾îÁö´Â ´Ü¹éÁú. Å¾Ʊ⳪ ÀÓ»êºÎ¿¡¼­ Á¤»óÀûÀ¸·Î Á¸ÀçÇÑ´Ù. ±×·¯³ª °£¾Ï¼¼Æ÷³ª »ý½Ä¼¼Æ÷¿¡ °ü·ÃµÈ Á¾¾ç¿¡¼­µµ ¸¸µé¾îÁ® ÀÌ·± Áúº´ÀÌ Á¸ÀçÇÒ ¶§¿¡´Â ÀÓ»êºÎ³ª Å¾ư¡ ¾Æ´Ï´õ¶óµµ Á¶Á÷À̳ª Ç÷¾×¿¡ ³ªÅ¸³ª°Ô µÈ´Ù. ÀÓ»óÀûÀ¸·Î´Â °£¾ÏÀ̳ª »ý½Ä¼¼Æ÷ Á¾¾çÀÇ ¹ß°ß°ú Ä¡·áÈ¿°ú ÆÇÁ¤¿¡ ÀÌ¿ëµÇ°í, ¶Ç ÀӽŠ16~18ÁÖ¿¡ »ê¸ðÀÇ Ç÷¾×¿¡¼­ À̴ܹéÁúÀÇ ¾çÀ» ÃøÁ¤ÇÏ¿© Å¾ÆÀÇ ºñÁ¤»óÀûÀΠ¹ß´ÞÀ» ¹ß°ßÇÒ ¼ö ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • subunit
    ¼Ò´ÜÀ§, ÇϺδÜÀ§
  • subunit vaccine
    ¾Æ´ÜÀ§¹é½Å
  • leukocyte inhibitory factor
    ¹éÇ÷±¸¾ïÁ¦ÀÎÀÚ
  • luteotrophic hormone inhibitory factor
    Ȳ(»ö)üÀÚ±ØÈ£¸£¸ó¾ïÁ¦ÀÎÀÚ
  • lymphocyte inhibitory factor
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • macrophage migration inhibitory factor
    Å«Æ÷½Ä¼¼Æ÷À̵¿ÀúÁöÀÎÀÚ, ´ë½Ä¼¼Æ÷À̵¿ÀúÁöÀÎÀÚ
  • prolactin inhibitory factor
    ÇÁ·Î¶ôƾºÐºñ¾ïÁ¦ÀÎÀÚ
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º¾ïÁ¦ÀÎÀÚ
  • alpha emitter
    ¾ËÆÄ¹æÃâü
  • alpha error
    ¾ËÆÄ¿À·ù, Á¦1Çü¿À·ù
  • alpha granule
    ¾ËÆÄ°ú¸³
  • alpha hemolysis
    ¾ËÆÄ¿ëÇ÷
  • alpha motor neuron
    ¾ËÆÄ¿îµ¿½Å°æ¼¼Æ÷
  • alpha ray
    ¾ËÆÄ¼±
  • alpha wave
    ¾ËÆÄÆÄ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • subunit
    ¼Ò´ÜÀ§, ¹Ø´ÜÀ§
  • leukemia cutis
    ÇǺιéÇ÷º´
  • leukemia
    ¹éÇ÷º´
  • alpha-interferon
    ¾ËÆÄÀÎÅÍÆä·Ð
  • alpha-adrenergics
    ¾ËÆÄ¾Æµå·¹³¯¸°¼º¾à
  • alpha-fetoprotein
    ¾ËÆÄžƴܹé
  • inhibitory action
    ¾ïÁ¦ÀÛ¿ë, ÀúÁöÀÛ¿ë
  • inhibitory enzyme
    ¾ïÁ¦È¿¼Ò
  • inhibitory effect
    ¾ïÁ¦È¿°ú
  • inhibitory hormone
    ¾ïÁ¦È£¸£¸ó
  • receptor blocker
    ¼ö¿ëüÂ÷´ÜÁ¦
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • receptor
    ¼ö¿ëü, ¼ö¿ë±â
  • antigen receptor
    Ç׿ø¼ö¿ëü
  • opiate receptor
    ¾ÆÆí¼ö¿ëü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • subunit
    ¼Ò´ÜÀ§, ¹Ø´ÜÀ§
  • subunit vaccine
    ¾Æ´ÜÀ§¹é½Å
  • leukocyte inhibitory factor
    ¹éÇ÷±¸¾ïÁ¦ÀÎÀÚ
  • luteotrophic hormone inhibitory factor
    ȲüÀÚ±ØÈ£¸£¸ó¾ïÁ¦ÀÎÀÚ
  • lymphocyte inhibitory factor
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • macrophage migration inhibitory factor
    Å«Æ÷½Ä¼¼Æ÷À̵¿ÀúÁöÀÎÀÚ
  • prolactin inhibitory factor
    ÇÁ·Î¶ôƾºÐºñ¾ïÁ¦ÀÎÀÚ
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º¾ïÁ¦ÀÎÀÚ
  • alpha-chymotrypsin
    ¾ËÆÄÄ«ÀÌ¸ðÆ®¸³½Å
  • alpha-fetoprotein
    ¾ËÆÄžƴܹé
  • alpha-interferon
    ¾ËÆÄÀÎÅÍÆä·Ð
  • alpha-lipoproteinemia
    ¾ËÆÄÁö¹æ´Ü¹éÇ÷Áõ
  • alpha emitter
    ¾ËÆÄ¹æÃâ±â
  • alpha error
    Á¦ÀÏÁ¾¿À·ù
  • alpha granule
    ¾ËÆÄ°ú¸³
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • prolactin-inhibitory factor(PIF)
    ÇÁ·Î¶ôƾ ºÐºñ ¾ïÁ¦ ÀÎÀÚ
  • alpha-adrenal receptor antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸°¼ö¿ëüÂ÷´ÜÁ¦
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸°¼ö¿ëü.
  • alpha-adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³¯¸°¼ö¿ëü
  • F factor (fertility factor)
    FÀÎÀÚ, ¼öÅÂÀÎÀÚ
  • GIP (Gastric inhibitory peptide)
    À§Àå¾ïÁ¦(êÖíóåäð¤) ÆéŸÀ̵å
  • Gastric inhibitory peptide
    À§¾ïÁ¦(êÖåäð¤)È£¸£¸ó
  • Hypothalamic inhibitory hormones
    ½Ã»óÇϺξïÁ¦È£¸£¸ó
  • IPSP = inhibitory postsynaptic potential
    ¾ïÁ¦¼º(åäð¤àõ)½Ã³À½ºÈÄ(ý­)Àü¾Ð(ï³äâ)
  • inhibitory action
    ÀúÁöÀÛ¿ë(îÁò­íÂéÄ).
  • inhibitory autacoid
    ¾ïÁ¦¿À¿ÀŸÄÚÀ̵å.
  • inhibitory concentration, minimum (MIC)
    ¾ïÁ¦ÃÖ¼Ò³óµµ
  • inhibitory effect
    ¾ïÁ¦È¿°ú(åäð¤ Íý).
  • inhibitory effect
    ¾ïÁ¦È¿°ú.
  • inhibitory enzyme
    ÀúÇØÈ¿¼Ò.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • influenza subunit vaccine
    ÀÎÇ®·ç¿£ÀÚ ¾Æ´ÜÀ§¹é½Å
  • subunit
    ¾Æ´ÜÀ§, ¼Ò´ÜÀ§
  • subunit vaccine
    ¾Æ´ÜÀ§ ¹é½Å
  • vaccine, subunit
    ¾Æ´ÜÀ§ ¹é½Å
  • alpha-adrenal receptor antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸°¼ö¿ëüÂ÷´ÜÁ¦
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸°¼ö¿ëü.
  • alpha-adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³¯¸°¼ö¿ëü
  • retinoid acid receptor alpha=RARA
    ¾ËÆÄ·¹Æ¼³ëÀÍ»ê¼ö¿ëü
  • luteotrop(h)ic hormone inhibitory factor =LTHIF
    ȲüÀÚ±ØÈ£¸£¸ó¾ïÁ¦ÀÎÀÚ(üÜô÷ô§Ð½¡­åäð¤ì×í­).
  • lymphocyte inhibitory factor (LIF)
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
  • macrophage migration inhibitory factor
    ´ë½Ä¼¼Æ÷ À¯ÁÖÀúÁöÀÎÀÚ.
  • migration inhibitory factor =MIF
    ´ë½Ä¼¼Æ÷À¯ÁÖÀúÁöÀÎÀÚ(ÓÞãÝá¬øàë´ñËîÁ ò­ì×í­).
  • migratory inhibitory factor
    À̵¿¼º ¾ïÁ¦ÀÎÀÚ
  • prolactin-inhibitory factor(PIF)
    ÇÁ·Î¶ôƾ ºÐºñ ¾ïÁ¦ ÀÎÀÚ
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º¾ïÁ¦ÀÎÀÚ (¡­åäð¤ì×í­).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Alpha cell [Glucagon cell]
    ¾ËÆÄ¼¼Æ÷ [±Û·çÄ«°ï¼¼Æ÷]
    [¿¾ ¿ë¾î] ¾ËÆÄ¼¼Æ÷
  • Receptor
    ¼ö¿ë±â
    [¿¾ ¿ë¾î] ¼ö¿ë±â
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Duffy factor
    ´õÇÇÀÎÀÚ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • leukemia
    ¹éÇ÷º´(ÛÜúìÜ»)
  • alpha adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³ª¸°ÀÛµ¿¼º(íÂÔÑàõ) ¼ö¿ëü(áôé»ô÷)
  • alpha receptor
    ¾ËÆÄ¼ö¿ëü(áôé»ô÷)
  • leukocyte inhibitory factor
    ¹éÇ÷±¸ÀúÇØÀÎÀÚ(ÛÜúìϹîÁúªì×í­)
  • gastric inhibitory peptide
    À§(êÖ) ÀúÇØ(îÁúª) ÆéŸÀ̵å
  • inhibitory autacoid
    ÀúÇØ(îÁúª)¿ÀŸÄÚÀ̵å
  • inhibitory medium
    "ÀúÇØ ¹è¾ç¾×(îÁúªÛÆå×äû), ÀúÇØ ¹èÁö(îÁúªÛÆò¢)"
  • inhibitory transmitter
    ÀúÇØ Àü´Þ¹°Áú(îÁúªîîÓ¹Úªòõ)
  • translationl inhibitory protein
    ¹ø¿ª ÀúÇØ ´Ü¹éÁú(Ûèæ»îÁúªÓ±ÛÜòõ)
  • catalytic subunit
    Ã˸žƴÜÀ§(õºØÚä¬Ó¤êÈ)
  • proteoglycan subunit
    ÇÁ·ÎÅ׿À±Û¶óÀÌÄ­ ¾Æ´ÜÀ§(ä¬Ó¤êÈ)
  • regulatory subunit
    Á¶Àý ¾Æ´ÜÀ§(ðàï½ä¬Ó¤êÈ)
  • ribosomal subunit
    ¶óÀ̺¸¼Ø ¾Æ´ÜÀ§(ä¬Ó¤êÈ)
  • ribosomal subunit exchange
    ¶óÀ̺¸¼Ø ¾Æ´ÜÀ§(ä¬Ó¤êÈ) ±³È¯(Îßüµ)
  • subunit
    ¾Æ´ÜÀ§(ä¬Ó¤êÈ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • receptor
    ¼ö¿ë±â, ¼ö¿ëü, °¨¼öü
  • aleukemic leukemia
    ¹«¹éÇ÷º´¼º¹éÇ÷º´
  • alpha
    ¾ËÆÄ
  • alpha fetoprotein
    ¾ËÆÄžƴܹé
  • alpha ray
    ¾ËÆÄ¼±
  • leukemia
    ¹éÇ÷º´
  • lymphocytic leukemia
    ¸²ÇÁ±¸¼º¹éÇ÷º´
  • attenuation factor
    °¨¾à¿ä¼Ò, °¨¼è¿äÀÎ
  • conversion factor
    º¯È¯ÀÎÀÚ
  • factor
    ÀÎÀÚ
  • predisposing factor
    ¼ÒÀÎ, Áúº´¼ÒÁú
  • Q factor
    Å¥ÀÎÀÚ
  • rheumatoid factor
    ·ù¸¶Æ¼½º¾çÀÎÀÚ
  • risk factor
    À§Çè¿äÀÎ
  • turbo factor
    Åͺ¸ÀÎÀÚ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
AML Acute Myelogenous Leukemia
  Morphologic Classification(FABºÐ·ù)
   &n...
CF calcaneal fibular [ligament]; calcium leucovorin; calf blood flow; calibration factor; cancer-free; ...
LIF laser-induced fluorescence; left iliac fossa; left index finger; leukemia-inhibiting factor; leukocy...
LIFR leukemia inhibitory factor receptor
MIF macrophage inhibitory factor; melanocyte[-stimulating hormone]-inhibiting factor; maximum inspirator...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
LIFR leukemia inhibitory factor receptor
G alpha G protein alpha subunit
alpha S alpha subunit
alpha SU alpha subunit
alpha T alpha subunit of transducin
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • subunit
    ¾Æ´ÜÀ§
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸° ¼ö¿ëü
  • effector-inhibitory factor
    È¿°ú±â ¾ïÁ¦ ÀÎÀÚ
  • macrophage migration inhibitory factor
    ´ë½Ä ¼¼Æ÷ À¯ÁÖ ÀúÁö ÀÎÀÚ, °Å½Ä ¼¼Æ÷ À¯ÁÖ ¾ïÁ¦ ÀÎÀÚ
  • migration inhibitory factor test
    À¯ÁÖ ÀúÁö ÀÎÀÚ ½ÃÇè
    ƯÀÌ Ç׿ø¿¡ ¹ÝÀÀÇÏ¿© ¸²ÇÁ±¸°¡ MIF¸¦ »ý¼ºÇÏ´Â µ¥ ´ëÇÑ »ýüÀÇ ½ÃÇè¹ýÀ¸·Î ¼¼Æ÷ ¸Å°³ ¸é¿ªÀ» Æò°¡ÇÏ´Â µ¥ »ç¿ëÇÑ´Ù. ÀϺΠ¸é¿ª °áÇÌ Áúº´, Áï DiGeorge ÁõÈıº, Wiskott-Aldrich ÁõÈıº, Hodgkin º´¿¡¼­´Â MIF°¡ »ý¼ºµÇÁö ¾Ê´Â´Ù.
  • virus inhibitory factor
    ¹ÙÀÌ·¯½º ¾ïÁ¦ ÀÎÀÚ
  • IGF-I : insulin like growth factor-IÀÇ ¾àÀÚ. ¼ºÀåÆÇÀÎ epiphyseal plate¿¡ ¿¬°ñ »ý¼ºÀ» Áõ°¡½ÃÄÑ »ÀÀÇ ¼ºÀåÀ» ÃËÁøÇÑ´Ù.

    IGF-II : insulin like growth factor-IIÀÇ ¾àÀÚ. ¸¹Àº Àå±â¿Í Á¶Á÷¿¡ ÀÛ¿ëÇÏ¿© ´Ü¹é ÇÕ¼º°ú DNA, RNAÀÇ ÇÕ¼ºÀ» Áõ°¡½ÃÄÑ ¼¼Æ÷ÀÇ ¼ö¿Í ¾çÀ» Áõ°¡

    Àν¶¸°¾ç ¼ºÀå ÀÎÀÚ °áÇÕ ´Ü¹éÁú
    insulinelike growth factor binding
  • single-factor versus multiple-factor analysis
    ´ÜÀÏ ¿ä¼Ò ºÐ¼® ´ë º¹ÇÕ ¿ä¼Ò ºÐ¼®
  • acute leukemia
    ±Þ¼º ¹éÇ÷º´
    ¿ø¹ßÇÏ´Â Á¶Ç÷ Á¶Á÷À̳ª ¹éÇ÷º´ ¼¼Æ÷ÀÇ Á¾·ù¿¡ µû¶ó °ñ¼ö¼º, ¸²ÇÁ¼º, ´Ü±¸¼ºÀ¸·Î ³ª´µ¾îÁö°í Ư¼öÇÑ °ÍÀ¸·Î¼­ Àû¹éÇ÷º´, ÇüÁú ¼¼Æ÷¼º ¹éÇ÷º´, È£»ê±¸¼º ¶Ç´Â È£¿°±â¼º ¹éÇ÷º´ µîÀÌ ÀÖ´Ù.
  • acute lymphoblastic leukemia
    ±Þ¼º ¸²ÇÁ¼º ¹éÇ÷º´
    1. À¯¾Æ ¹× ÀþÀº ¼ºÀο¡ È£¹ßÇÏ´Â Áúȯ. À¯¾Æ ±Þ¼º ¹éÇ÷º´ÀÇ »ó´ç¼ö¸¦ Â÷ÁöÇÑ´Ù. À¯¾Æ¿¡¼­ÀÇ È£¹ß ¿¬·ÉÀº 4¼¼ ÀüÈÄ. ÃÖ±Ù È­Çпä¹ýÀ¸·Î º´¿¡ °É¸° À¯¾ÆÀÇ 90%°¡ ¿ÏÀü Ä¡À¯µÈ´Ù. ¿¹ÈÄ´Â ¿¬·É, ¸é¿ªÇ¥ÇöÇü ±×¸®°í ¼¼Æ÷ À¯ÀüÇÐÀûÀÎ º¯È­¿¡ ÀÇÇØ ¿µÇâÀ» ¹Þ´Â´Ù. 2. ȯÀÚÀÇ 90%°¡ ¹éÇ÷±¸ ¼¼Æ÷¿¡¼­ ÇÙÇü ÀÌ»óÀ» º¸ÀδÙ. ÀϺΠ¼¼Æ÷À¯Àü º¯È­°¡ ¼ºº°, ¿¬·É, ¸é¿ªÇ¥ÇöÇü °°Àº º¯ÀÌ¿ä¼Ò¿Í »ó°ü¾øÀÌ ¿¹ÈÄ¿¡ ´ëÇÑ Á¤º¸¸¦ ÁØ´Ù. 51-60 ¿°»öü »çÀÌÀÇ °í¹è¼ö¼ºÀÌ ¿¹Èİ¡ ÁÁÀº °ÍÀº ÀÌ¹Ì Àß ¾Ë·ÁÁ® ÀÖ´Ù.
  • acute megakaryocytic leukemia
    ±Þ¼º °ÅÇÙ±¸¼º ¹éÇ÷º´
  • acute mixed-lineage leukmia£¨±Þ¼º È¥ÇÕ-Á÷°è¼º ¹éÇ÷º´£©

    acute monocytic leukemia

    ±Þ¼º ´Ü±¸ ¹éÇ÷º´, ±Þ¼º ´Ü±¸¼º ¹éÇ÷º´
    ±Þ¼º ¹éÇ÷º´ÀÇ ÀÏÁ¾À̰í À¯¾à´Ü±¸°¡ ¹éÇ÷º´È­ÇÑ °ÍÀÌ´Ù. °ñ¼ö¿¡¼­ °ú¸³±¸°èÀÇ À¯¾à¼¼Æ÷¿Í ´Ü±¸°èÀÇ À¯¾à¼¼Æ÷°¡ È¥ÀçÇÏ´Â ¼ö°¡ ÀÖ°í ÀÌ °æ¿ì¿¡´Â ±Þ¼º °ñ¼ö´Ü±¸¼º ¹éÇ÷º´À̶ó°í ÇÑ´Ù.
  • acute myelocytic leukemia
    ±Þ¼º °ñ¼ö±¸¼º ¹éÇ÷º´
    ±Þ¼ºÀ¸·Î ¹ßº´ ÁøÇàµÇ´Â °ñ¼ö¼¼Æ÷ ±â¿øÀÇ ¹éÇ÷º´À¸·Î º¸Åë ¿­°ú ÇÔ²² ÀϾ´Ù.
  • acute myelomonoblastic leukemia
    ±Þ¼º °ñ¼ö ´Ü±¸¼º ¹éÇ÷º´
  • adult T cell leukemia
    ¼ºÀÎ T¼¼Æ÷ ¹éÇ÷º´
    ¹ßÁõ ¿¬·ÉÀº Æò±Õ 51¼¼, ÀϺ» Kyushu, Shikoku, Kii ¹Ýµµ Áö¹æ¿¡¼­ ´Ù¹ßÇϰí ÇǺΠħÀ± ¹× °£Àå, ºñÀå, ¸²ÇÁÀý Á¾´ë¸¦ ÈçÈ÷ º¼ ¼ö Àִµ¥ ºóÇ÷Àº ¾ø´ø°¡, À־ °æµµ, °ñ¼ö¿¡ÀÇ Ä§À±Àº º¸Åë ÇöÀúÇÏÁö ¾Ê´Ù. 50% »ýÁ¸Àº 4.4°³¿ù·Î ª´Ù. ¹éÇ÷º´ ¼¼Æ÷ÀÇ Æ¯Â¡Àº ÇÙÀÌ ÀÌÇüÀÌ¸ç ºÐ¿±»ó, È­ÆÇ»ó µîÀ¸·Î Áø´Ü¿¡ »ç¿ëµÈ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
leukemia <haematology> An acute or chronic disease of unknown cause in man and other warm blooded animals that involves the blood forming organs, is characterised by an abnormal increase in the number of leucocytes in the tissues of the body with or without a corresponding increase of those in the circulating blood and is classified according of the type leucocyte most prominently involved.
(18 Nov 1997)
glycoprotein hormones, alpha subunit A non-covalently bound subunit of the glycoprotein hormones tsh, fsh, lh, and hcg which originates in the anterior pituitary gland and placenta. This subunit is virtually identical in structure and indistinguishable by radioimmunoassay in all of the above glycoproteins. It is present in both men and women, but is elevated in postmenopausal women and in patients with hypothyroidism, uraemia and malignant tumours. The alpha subunit may be involved directly in recognition of certain receptors.
(12 Dec 1998)
phycocyanin alpha-subunit phycocyanobilin lyase <enzyme> Cleaves thioether bond attaching phycocyanobilin to the alpha subunit of phycocyanin; product of the cpce and cpcf genes of synechococcus
Registry number: EC 4.4.-
Synonym: phycocyanobilin lyase
(26 Jun 1999)
phycoerythrocyanin alpha-subunit phycobiliviolin lyase <enzyme> Shows high degree of homology to phycocyanobilin lyase
Registry number: EC 4.4.-
Synonym: phycobiliviolin lyase, pece protein, pecf protein, pec alpha-subunit phycobiliviolin lyase
(26 Jun 1999)
migration-inhibitory factor <growth factor> A soluble, nondialysable factor that is produced by sensitised lymphocytes following exposure to a specific antigen. It inhibits macrophage migration and causes adherence.
It was originally defined on the basis of inhibition of emigration of mononuclear cells from capillary (haematocrit) tubes, more recently a 13 kD protein with migration inhibitory activity has been isolated.
Acronym: MIF
Synonym: inhibition factor.
(22 Sep 2002)
migration-inhibitory factor test A test which measures the presence of migration-inhibitory factor. Usually peritoneal macrophages are placed in a capillary tube in the presence or absence of supernatants from activated T-cells. If MIF is present, the migration of monocyte/macrophages is reduced.
Synonym: macrophage migration inhibition test, migration inhibition test.
(05 Mar 2000)
Leukaemia inhibitory factor <growth factor> Polypeptide growth factor or cytokine with wide range of activities. Regulates growth and differentiation of primordial germ cells and embryonic stem cells but has effects on peripheral neurons, osteoblasts, adipocytes and various cells of the myeloid lineage. Given to adult animals induces weight loss, behavioural disorders and bone abnormalities. Many of the effects of LIF in vitro can be mimicked by IL-6, oncostatin M and ciliary neurotrophic factor, all of which interact indirectly with gp130, a shared tranducer subunit.
(18 Nov 1997)
gene rearrangement, alpha-chain T-cell antigen receptor Ordered rearrangement of T-cell variable gene regions coding for the alpha-chain of antigen receptors.
(12 Dec 1998)
genes, T-cell receptor alpha DNA sequences encoding the alpha chain of the T-cell receptor. The genomic organization of the tcr alpha genes is essentially the same in all species and is similar to the organization of ig genes.
(12 Dec 1998)
gamma subunit, cGMP phosphodiesterase <enzyme> Isolated from canine retinal rod photoreceptor cells; genbank u49359
Registry number: EC 3.1.14.-
Synonym: pde-gamma, pdegamma, cgmp-pde gamma subunit
(26 Jun 1999)
ribulose-1,5-bisphosphate carboxylase-oxygenase large subunit epsilonN-methyltransferase <enzyme> An aspect of EC 2.1.1.43; trimethylates lys-14 of rubisco
Registry number: EC 2.1.1.-
Synonym: rubisco lsmt, rubisco large subunit lysine n-methyltransferase
(26 Jun 1999)
cholera toxin, B subunit-horseradish peroxidase <chemical> Conjugate of horseradish peroxidase and cholera toxin
Synonym: bhrp, horseradish peroxidase-cholera toxin b subunit, cholera toxin-horseradish peroxidase, horseradish peroxidase-cholera toxin, ib4-hrp
(26 Jun 1999)
chorionic gonadotropin, beta subunit, human The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (scan j clin lab invest suppl 1993;216:97-104)
(12 Dec 1998)
signal peptide p25-subunit IV cytochrome oxidase <chemical> Similar in action to melittin
Synonym: p25 presequence peptide-cytochrome oxidase, pre-ctox p25
(26 Jun 1999)
subunit <cell biology> Components from which a structure is built, thus myosin has six subunits, microtubules are built of tubulin subunits. In some cases it may be more informative to speak of protomers.
(06 Mar 1998)
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 1 ÆäÀÌÁö: 1
  • Leukemia Inhibitory Factor Receptor alpha Subunit - »õâ A receptor subunit that combines with CYTOKINE RECEPTOR GP130 to form the dual specificity receptor for LEUKEMIA INHIBITORY FACTOR and ONCOSTATIN M. The subunit is also a component of the CILIARY NEUROTROPHIC FACTOR RECEPTOR. Both membrane-bound and secreted isoforms of the receptor subunit exist due to ALTERNATIVE SPLICING of its mRNA. The secreted isoform is believed to act as an inhibitory receptor, while the membrane-bound form is a signaling receptor.
    Synonyms : CD118 Antigen, LIF Receptor alpha Subunit, Antigen, CD118
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • subunit
    ¾Æ´ÜÀ§;¼­ºêÀ¯´ÏÆ®(»ýüÀÔÀÚ(°íºÐÀÚ)¸¦ ÀÌ·ç´Â ±âº» ´ÜÀ§)
  • inhibitory
    ±ÝÁöÀÇ
  • inhibitory
    ±ÝÁöÀÇ;Á¦Áö(¾ïÁ¦)ÇÏ´Â
  • receptor
    ¼ö¿ë±â;°¨°¢±â°ü;¼ö¿ëü
  • receptor site
    ¼¼Æ÷³» ¼ö¿ë ¿µ¿ª
  • leukemia
    ¹éÇ÷º´
  • leukemia
    ¹éÇ÷º´
  • leukemia
    ¹èÇ÷(±¸ °ú´Ù)Áõ !
  • alpha
    ¾ËÆÄ
  • alpha
    ±×¸®½ºÀÚ¸ðÀÇ Ã¹Â°±ÛÀÚ
  • alpha particle
    ¾ËÆÄÀÔÀÚ
  • alpha plus
    ÃÖ°í±ÞÀÇ
  • alpha rays
    ¾ËÆÄ¼±
  • alpha rhythm
    (³úÆÄÀÇ)¾ËÆÄ¸®µë
  • alpha test
    Áö´ÉÅ×½ºÆ®
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á